Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ebola Success For Regeneron’s Triple Antibody Cocktail

Executive Summary

PALM study stopped early after two agents being tested proved better than ZMapp, the current standard of care, in the ongoing Ebola outbreak in the Democratic Republic of Congo. One is being developed by Regeneron.

You may also be interested in...



Mid-Sized Pharmas Mostly Seeing Valuations Rise During Pandemic

Six of seven mid-sized companies enjoyed valuation increases over the first quarter, with four firms up by 7.5% or more. Some are benefiting from direct involvement in addressing the COVID-19 pandemic.

COVID-19 Study Of Gilead’s Remdesivir Using Ebola-Style Adaptive Platform Trial

First COVID-19 experimental treatment trial in US is a master protocol that echoes NIH’s Ebola treatment approach.

China Makes Its Mark On R&D Pipeline And Novel Launches

The largest-ever rise in the number of active R&D companies, particularly in China, helped propel an unprecedented increase in the size of the biopharma pipeline in 2019. Meanwhile, the number of new active substances launched in their first market last year dropped as 2018’s superlative performance gave way to something more usual.

Topics

Related Companies

UsernamePublicRestriction

Register

LL021506

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel